Extended Data Table 1 Concordance of pathological and radiographic response

From: Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial

  1. All 57 patients who underwent surgery had both pathological and radiographic response data. CR, complete response; PD, progressive disease; pCR, pathological complete response; pNR, pathological non-response; pPR, pathological partial response; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.
Back to article page